Departamento de Biologia, Universidad Argentina John F Kennedy, Buenos Aires, Argentina.
Peptides. 2012 Apr;34(2):349-52. doi: 10.1016/j.peptides.2012.02.008. Epub 2012 Feb 19.
The chronic hyperglycemia measured alongside diabetes development is associated with significant long-term damage and failure of various organs. In the present study it was shown that hyperglycemia induced early and long term increases in nitric oxide (NO) levels, kallikrein activity and vascular capillary permeability measured as plasma extravasation, and decreases of Na/K ATPase activity in diabetic rat retina 4 and 12 weeks after streptozotocin (STZ) injection. Treatment of the animals for 5 consecutive days with a novel selective bradykinin B(1) receptor (BKB(1)-R) antagonist R-954 (2mg/kg s.c) at the end of the 4 and 12 week periods highly reduced NO, kallikrein and capillary permeability and increased Na/K ATPase activity in the retina. These results suggest that the BKB(1)-R receptor subtype is over-expressed during the streptozotocin-induced development of diabetes in rat retina as evidenced by the inhibitory effects of the BKB(1)-R antagonist R-954 on NO, kallikrein and vascular permeability increases as well as Na/K ATPase decreases. The beneficial role of the BKB(1)-R antagonist R-954 for the treatment of the diabetic retinopathy is also suggested.
与糖尿病发展同时测量的慢性高血糖与各种器官的显著长期损伤和衰竭有关。在本研究中表明,高血糖诱导了糖尿病大鼠视网膜中一氧化氮(NO)水平、激肽释放酶活性和血管毛细血管通透性(作为血浆渗出测量)的早期和长期增加,以及在链脲佐菌素(STZ)注射后 4 和 12 周时 Na/K ATPase 活性的降低。在第 4 和 12 周结束时,连续 5 天每天用新型选择性缓激肽 B(1)受体(BKB(1)-R)拮抗剂 R-954(2mg/kg sc)对动物进行治疗,可高度降低视网膜中的 NO、激肽释放酶和毛细血管通透性,并增加 Na/K ATPase 活性。这些结果表明,在大鼠视网膜的链脲佐菌素诱导的糖尿病发展过程中,BKB(1)-R 受体亚型过度表达,这可通过 BKB(1)-R 拮抗剂 R-954 对 NO、激肽释放酶和血管通透性增加以及 Na/K ATPase 降低的抑制作用得到证明。BKB(1)-R 拮抗剂 R-954 对糖尿病性视网膜病变的治疗作用也得到了提示。
Curr Opin Investig Drugs. 2010-5
Br J Pharmacol. 2018-2-13
Invest Ophthalmol Vis Sci. 1997-3
Invest Ophthalmol Vis Sci. 1996-7
Exp Eye Res. 2011-3-21
Medicina (Kaunas). 2023-7-20
Invest Ophthalmol Vis Sci. 2021-10-4
Int J Mol Sci. 2021-8-31
Adv Exp Med Biol. 2019
J Clin Med. 2019-8-1
Br J Pharmacol. 2018-2-13
J Clin Endocrinol Metab. 2017-12-1
Pathophysiology. 2017-12